<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962958</url>
  </required_header>
  <id_info>
    <org_study_id>2021-KY-047</org_study_id>
    <nct_id>NCT04962958</nct_id>
  </id_info>
  <brief_title>Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery</brief_title>
  <official_title>Prospective, Single-arm, Multicenter Clinical Study of Hepatic Artery Infusion Chemotherapy With Donafenib for Adjuvant Treatment of HCC Patients With High Risk of Recurrence After Hepatectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mengchao Hepatobiliary Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label，multi-center ，non-randomized ，single arm exploratory study . This&#xD;
      clinical study is an investigator-initiated clinical trial（IIT ）. The objective of this study&#xD;
      is to evaluate if the addition of hepatic artery infusion chemotherapy (HAIC) and Donafenib&#xD;
      after curative resection for hepatocellular carcinoma patients with a solitary tumor≥5 cm and&#xD;
      microvascular invasion （MVI） will prevent or delay the recurrence of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year cumulative recurrence-free survival rate</measure>
    <time_frame>2-year</time_frame>
    <description>This is defined as the length of time (days) that the patient survives since study registration without any signs or symptoms of locoregional HCC assessed by structured clinical and radiological (clinical) follow-up . If at close-out date of the study, there are no signs of locoregional recurrence, the patient will be censored to the date of the most recent follow-up examination. The 2-year cumulative incidence rates will be estimated from the curves and its associated 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year recurrence-free survival rate</measure>
    <time_frame>1-year</time_frame>
    <description>This is defined as the length of time (days) that the patient survives since study registration without any signs or symptoms of locoregional HCC assessed by structured clinical and radiological (clinical) follow-up . If at close-out date of the study, there are no signs of locoregional recurrence, the patient will be censored to the date of the most recent follow-up examination. The 1-year cumulative incidence rates will be estimated from the curves and its associated 95% confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2-year</time_frame>
    <description>from the date of enrollment to tumor recurrence or Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>approximately 60 months from first patient first visit</time_frame>
    <description>from the date of enrollment to Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of adverse events. Postoperative adverse events were graded based on CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Carcinoma</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Antineoplastic Agents</condition>
  <condition>Donafenib</condition>
  <condition>Fluorouracil</condition>
  <condition>Oxaliplatin</condition>
  <condition>Antimetabolites</condition>
  <arm_group>
    <arm_group_label>HAIC+Donafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic arterial infusion chemotherapy</intervention_name>
    <description>administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries</description>
    <arm_group_label>HAIC+Donafenib</arm_group_label>
    <other_name>HAIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfox Protocol</intervention_name>
    <description>Oxaliplatin , fluorouracil, and leucovorin</description>
    <arm_group_label>HAIC+Donafenib</arm_group_label>
    <other_name>Oxaliplatin , fluorouracil, and leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib</intervention_name>
    <description>administration of Donafenib</description>
    <arm_group_label>HAIC+Donafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years, male or female;&#xD;
&#xD;
          2. Naive patients with hepatocellular carcinoma pathologically diagnosed who have&#xD;
             Underwent radical hepatectomy 4-8 weeks before enrollment;&#xD;
&#xD;
          3. HCC patients with a solitary tumor≥5 cm and Microvascular invasion;&#xD;
&#xD;
          4. Child-Pugh score A/B(≤7);&#xD;
&#xD;
          5. ECOG PS score 0-1;&#xD;
&#xD;
          6. No residual tumor lesions were confirmed on imaging more than 4 weeks after surgery;&#xD;
&#xD;
          7. The main organ functions meet the following criteria within 14 days before enrollment;&#xD;
             (1)Hemoglobin(HB)≥100 g/L (2)neutrophils(ANC)≥1.5×10^9 /L, (3)platelet&#xD;
             count(PLT)≥75×10^9/L; (4)ALB≥28g/L (5)alanine aminotransferase(ALT), aspartate&#xD;
             aminotransferase(AST)&lt;5×ULN (6)Total bilirubin (TBIL)&lt;1.5×ULN (7)Plasma creatinine&#xD;
             ≤1.5×ULN with a creatinine clearance≥50mL/min (8)Activation Partial Thrombin&#xD;
             Activation Time (APTT) and International Normalized Ratio (INR)≤1.5×ULN&#xD;
&#xD;
          8. Subjects voluntarily enrolled in the study, signed an informed consent form, followed&#xD;
             well and cooperated with the follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received any hepatocellular carcinoma-related systemic therapy&#xD;
             before enrollment; including targeted therapy such as sorafenib, lenvatinib, and&#xD;
             regorafenib, or immunomodulators such as anti-PD-1, anti-PD-L1, and anti-CTLA-4&#xD;
             Treatment, excluding antiviral treatment; if the patient has used traditional Chinese&#xD;
             medicine with anti-tumor indications, it must be&gt; 2 weeks or 5 drug half-lives&#xD;
             (whichever is longer). Patients whose adverse events caused by treatment have not&#xD;
             recovered to ≤ CTCAE Grade 1;&#xD;
&#xD;
          2. Patients who have received other adjuvant treatments (except antiviral therapy) after&#xD;
             radical hepatectomy, including adjuvant local treatments (such as transarterial&#xD;
             chemoembolization [TACE]);&#xD;
&#xD;
          3. Hepatic veins, portal veins, bile ducts, or inferior vena cava can be visually or&#xD;
             microscopically seen with tumor thrombi&#xD;
&#xD;
          4. Diagnosed with lymph node invasion or extrahepatic metastasis;&#xD;
&#xD;
          5. Number of tumors≥2;&#xD;
&#xD;
          6. A history of other malignant tumours within the last five years, except for cured skin&#xD;
             basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer,&#xD;
             cervical carcinoma in situ or other carcinoma in situ;&#xD;
&#xD;
          7. Pregnant or breastfeeding women; males or females of childbearing age who are&#xD;
             unwilling or unable to take effective contraceptive measures&#xD;
&#xD;
          8. Known history of alcohol, psychotropic drug or other drug abuse within 6 months before&#xD;
             entry into the study 9.Those the researcher deems inappropriate for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Zhang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Zhang, PHD</last_name>
    <phone>86-136-0273-0646</phone>
    <email>zhangl9@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Zhang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lei Zhang, PHD</last_name>
      <phone>+8613602730646</phone>
      <email>zhangl9@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Hepatic arterial infusion chemotherapy</keyword>
  <keyword>Donafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

